$MENS News

Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California

Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates

Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates

Jyong Biotech Plans Potential Texas Manufacturing Facility And U.S. Operations Center To Support Future Commercialization Of Drug Candidates

Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia

CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan

Jyong Biotech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 66.30%

Jyong Biotech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 42.20%

Jyong Biotech Responds to Share Price and Volume Movement